These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9717492)

  • 1. The use of abciximab during percutaneous coronary angioplasty reduces ischaemic events, but the cost is prohibitive.
    Mayosi BM; Latouf SE; Commerford PJ
    S Afr Med J; 1998 Feb; 88(2):130-1. PubMed ID: 9717492
    [No Abstract]   [Full Text] [Related]  

  • 2. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data.
    Mark DB; Simons TA
    Am Heart J; 1999 May; 137(5):S123-5. PubMed ID: 10220613
    [No Abstract]   [Full Text] [Related]  

  • 3. [Medico-economic evaluation of abciximab].
    Le Pen C; Bonastre J; Pinton P
    Ann Cardiol Angeiol (Paris); 1999 Jan; 48(1):80-6. PubMed ID: 12555363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. An industry perspective on health economics studies.
    Anderson KM; Bala MV; Weisman HF
    Am Heart J; 1999 May; 137(5):S129-32. PubMed ID: 10220615
    [No Abstract]   [Full Text] [Related]  

  • 5. Enthusiasm, reality, and cost-effectiveness analysis.
    Brophy JM; Sleight P
    Heart; 1998 Jan; 79(1):9-10. PubMed ID: 9505910
    [No Abstract]   [Full Text] [Related]  

  • 6. The economics of adjunctive therapies in coronary angioplasty: drugs, devices, or both?
    Oh PI; Cohen EA; Mittmann N; Seung SJ
    Can J Clin Pharmacol; 2004; 11(2):e202-11. PubMed ID: 15520474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Abciximab (c7E3)--a new monoclonal antibody--from the pharmaco-economic viewpoint. Initial reports from the literature].
    Sturm C
    Med Klin (Munich); 1996 Nov; 91(11):735-8. PubMed ID: 9036301
    [No Abstract]   [Full Text] [Related]  

  • 8. Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes.
    Exaire JE; Lincoff AM
    J Thromb Haemost; 2004 Jan; 2(1):7-9. PubMed ID: 14717958
    [No Abstract]   [Full Text] [Related]  

  • 9. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.
    van Hout BA; Bowman L; Zelinger DJ; Simoons ML
    Eur Heart J; 1998 Apr; 19 Suppl D():D59-66. PubMed ID: 9597523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murmurs from the heart (or why the stethoscope is not an economic tool).
    Aristides M; Gliksman M
    Heart; 1998 Jan; 79(1):10-1. PubMed ID: 9518073
    [No Abstract]   [Full Text] [Related]  

  • 11. Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation.
    Dunn CJ; Foster RH
    Pharmacoeconomics; 1999 Dec; 16(6):711-41. PubMed ID: 10724797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost and outcomes analysis of abciximab use in a community teaching hospital.
    Abernathy GB; Hewitt KK
    Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S35-7. PubMed ID: 9872696
    [No Abstract]   [Full Text] [Related]  

  • 13. Are stenting and glycoprotein IIb/IIIa blockade of good value in primary percutaneous coronary intervention?
    Cole JH; Weintraub WS
    Circulation; 2003 Dec; 108(23):2831-3. PubMed ID: 14662689
    [No Abstract]   [Full Text] [Related]  

  • 14. Routine use of abciximab in coronary stenting?
    Stables RH
    Lancet; 1998 Jul; 352(9122):81-2. PubMed ID: 9672267
    [No Abstract]   [Full Text] [Related]  

  • 15. Difficulties in applying clinical trial information to the practice setting: case of a high-cost drug.
    Reed SD; Mullins CD; Roffman DS; Mays DA
    Am J Health Syst Pharm; 1998 Nov; 55(22):2409-14. PubMed ID: 9825038
    [No Abstract]   [Full Text] [Related]  

  • 16. Costs and effects of c7E3 in high risk PTCA patients. An indirect analysis for The Netherlands.
    van Hout BA; Simoons ML
    Eur Heart J; 1995 Nov; 16 Suppl L():81-5. PubMed ID: 8869024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abciximab provides cost-effective survival advantage in high-volume interventional practice.
    Kereiakes DJ; Obenchain RL; Barber BL; Smith A; McDonald M; Broderick TM; Runyon JP; Shimshak TM; Schneider JF; Hattemer CR; Roth EM; Whang DD; Cocks D; Abbottsmith CW
    Am Heart J; 2000 Oct; 140(4):603-10. PubMed ID: 11011333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [An economic assessment of the use of abciximab as a coronary angioplasty preparation in the Italian health-care context].
    Lorenzoni R; Mazzotta G; Gensini GF; De Caterina R
    G Ital Cardiol; 1999 Mar; 29(3):269-76. PubMed ID: 10231672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abciximab therapy in percutaneous intervention: economic issues in the United States.
    Goklaney AK; Murphy JD; Hillegass WB
    Am Heart J; 1998 Apr; 135(4):S90-7. PubMed ID: 9539499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and cost effectiveness of single bolus treatment with abciximab (Reo Pro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high risk patients.
    Aristides M; Gliksman M; Rajan N; Davey P
    Heart; 1998 Jan; 79(1):12-7. PubMed ID: 9505912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.